{
  "docId": "019de076-b8a1-76db-a88b-3941d3b29d31",
  "docSlug": "785649d6ad3bf1f87bd264132bed44c1",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 25,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b8a1-76db-a88b-3941d3b29d31/3",
  "deckHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31",
  "deckJsonHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31.json",
  "deckAnchorHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.562
      },
      "kind": "list",
      "text": "NXP900: Phase 1a dose escalation ongoing; First potential indications: YES1/SRC-driven solid tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21bead34-1ab2-4f78-87c3-556ba53a5daf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.238
      },
      "kind": "list",
      "text": "Our Approach to Precision Medicine: Select and acquire novel, rationally-designed drug candidates; Focus on drug development for serious conditions of unmet need in oncology",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f3ba247-1b91-423f-9d71-872843771bb2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.4
      },
      "kind": "list",
      "text": "NXP800: Ongoing expansion cohorts: ARID1a-mutated, platinum resistant ovarian carcinoma (Fast Track Designation); Cholangiocarcinoma (Orphan Drug Designation)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9760f591-b364-4579-9479-806baef2f654",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.724
      },
      "kind": "list",
      "text": "Management Team with Strong Track Record: 3 approved drugs in 4 indications in the US and EU and multiple strategic deals; Cash runway into 1H2025",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6d97f96-399a-42ea-8f6c-b96ed9cd1822",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Nuvectis Pharma – Key Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7733372d-9c6a-42df-88c9-0d802e4f5253",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "1f03f267-74e9-45f1-9ae5-75337e05e7d5",
      "evidence": "Nuvectis Pharma – Key Highlights list",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 13,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "091b1497-af72-44f0-adc3-01a8fe42e431",
      "evidence": "Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts",
      "position": 0,
      "objective": "Highlight the need for new cancer treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}